Video Experimental Relacionado
Updated: Jul 25, 2026
09:02
Percutaneous Hepatic Perfusion (PHP) with Melphalan as a Treatment for Unresectable Metastases Confined to the Liver
Published on: July 31, 2016
Quimioterapia oral con melfalán y prednisona más talidomida en comparación con melfalán y prednisona en solitario en
Antonio Palumbo1, Sara Bringhen, Tommaso Caravita
1Divisione di Ematologia dell'Università di Torino, Azienda Ospedaliera S Giovanni Battista, 10126 Torino, Italy. appalumbo@yahoo.com
Lancet (London, England)
|March 15, 2006
Resumen
La adición de talidomida a melfalán oral y prednisona (MPT) mejora significativamente las tasas de respuesta y la supervivencia libre de eventos en pacientes ancianos con mieloma múltiple. La profilaxis con anticoagulantes es crucial para reducir el riesgo de trombosis.
Área de la Ciencia:
- Hematología Hematología.
- Oncología Oncología.
- Los ensayos clínicos son ensayos clínicos.
Sus antecedentes:
- El melfalán y la prednisona (MP) por vía oral han sido el tratamiento estándar para pacientes ancianos con mieloma múltiple desde 1960.
- Este estudio investigó la eficacia de la adición de talidomida al régimen estándar de MP.
Objetivo del estudio:
- Para comparar la eficacia y seguridad del melfalan oral, la prednisona y la talidomida (MPT) frente al melfalan oral y la prednisona (MP) sola.
- Evaluar las tasas de respuesta y la supervivencia libre de eventos en pacientes ancianos con mieloma múltiple recién diagnosticado.
Principales métodos:
- Un ensayo multicéntrico aleatorizado asignó a pacientes de 60 a 85 años de edad a recibir MPT oral o MP solo durante seis ciclos de 4 semanas.
- La talidomida se administró en 100 mg diarios hasta la progresión o recaída de la enfermedad.
- Se realizó un análisis de intención de tratar; el ensayo está registrado bajo NCT00232934.4.
Principales resultados:
- La MPT demostró tasas de respuesta significativamente más altas (76,0% frente a 47,6%) y una mejor supervivencia libre de eventos a los 2 años (54% frente a 27%) en comparación con la MP sola.
- Las tasas de respuesta casi completa o completa fueron sustancialmente más altas en el brazo de MPT (27,9% frente a 7,2%).
- Los eventos adversos de grado 3 o 4 fueron más frecuentes en el grupo de MPT (48% vs. 25%), pero la profilaxis de enoxaparina redujo las tasas de tromboembolismo del 20% al 3%.
Conclusiones:
- La MPT oral es un tratamiento efectivo de primera línea para pacientes ancianos con mieloma múltiple, mejorando los puntos finales clave de eficacia.
- El uso de la profilaxis anticoagulante es esencial para mitigar el mayor riesgo de trombosis asociado con MPT.
- Se requiere un seguimiento adicional para determinar el impacto a largo plazo de la MPT en la supervivencia general.
Videos de Conceptos Relacionados
02:56Treatment Resistant Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
02:56Treatment Resistent Cancers
Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
01:29Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel Disease...
01:21Drugs for Treatment of Crohn's Disease in IBD Using Glucocorticoids
Glucocorticoids, a class of anti-inflammatory drugs, are pivotal in treating moderate to severe Crohn's disease by inducing remission. They exhibit their anti-inflammatory action by inhibiting the production of inflammatory cytokines such as tumor necrosis factor (TNF)-α, interleukin (IL)-1, and chemokines like IL-8. In addition, they reduce the expression of inflammatory cell adhesion molecules and inhibit gene transcription of nitric oxide synthase, phospholipase A2, cyclooxygenase-2 (COX-2),...
01:27Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
01:25Dosage Regimen: Multiple Oral Dosage
Understanding how a drug's concentration fluctuates within the body over time is crucial in pharmacokinetics, particularly with multiple oral doses. A graphical representation of multiple oral dosages provides insight into these dynamics. Typical accumulation curves of a drug's concentration in the body reveal a sawtooth pattern, indicating periodic peaks and troughs correlating with each dose administration and the drug's subsequent elimination.The plasma concentration at any time during an...